Latest filing published 07 Aug 2026 for Tiziana Life Sciences Ltd, €14k.
Across 13 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Gabriele M. Cerrone is a declared insider at 3 companies (chief executive); the most frequent names are Accustem Sciences Inc., OKYO Pharma Ltd and Tiziana Life Sciences Ltd. Over a trading history stretching from 25 April 2022 to 21 July 2026, the count stands at 32 filings.
No open-market sale appears; the market trades are 25 purchases worth €1.1M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 5 share grants. In 2026 alone, the filings show 4 purchases and no sales.
In size, the median ticket on the buying side is €14k. Relative to company size, the median is 0.037% of market cap (4 purchases with a known value). Of 22 purchases, 2 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.
On 7 August 2026 came the latest disclosure, an open-market purchase for €31k in OKYO Pharma Ltd. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 28 declarations